MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.27
-0.41 (-2.46%)
At close: Mar 20, 2026, 4:00 PM EDT
16.48
+0.21 (1.29%)
After-hours: Mar 20, 2026, 7:40 PM EDT
MLTX Employees
MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year.
Employees
130
Change (1Y)
30
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,748,600
Market Cap
1.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 30 | 30.00% |
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| EyePoint | 214 |
| Monte Rosa Therapeutics | 150 |
| Precigen | 143 |
| Olema Pharmaceuticals | 131 |
| Septerna | 130 |
| Kodiak Sciences | 123 |
| ORIC Pharmaceuticals | 104 |
MLTX News
- 26 days ago - MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal - Seeking Alpha
- 27 days ago - MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript - Seeking Alpha
- 27 days ago - MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain - Benzinga
- 5 weeks ago - ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - GlobeNewsWire
- 6 weeks ago - MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - GlobeNewsWire
- 7 weeks ago - Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - GlobeNewsWire
- 2 months ago - MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission - Seeking Alpha